Cridanimod
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Cridanimod
- DrugBank Accession Number
- DB13674
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 253.2527
Monoisotopic: 253.073893223 - Chemical Formula
- C15H11NO3
- Synonyms
- Cridanimod
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Cridanimod sodium 54W868ROLR 58880-43-6 FQMLTEAEJZVTAJ-UHFFFAOYSA-M
Categories
- ATC Codes
- L03AX18 — Cridanimod
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as acridones. These are acridines containing a ketone group attached to the C9 carbon atom of the acridine moiety.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Benzoquinolines
- Direct Parent
- Acridones
- Alternative Parents
- Hydroquinolones / Hydroquinolines / Alpha amino acids and derivatives / Pyridines and derivatives / Benzenoids / Vinylogous amides / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds show 5 more
- Substituents
- Acridone / Alpha-amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Dihydroquinoline / Dihydroquinolone show 11 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- X91E9EME19
- CAS number
- 38609-97-1
- InChI Key
- UOMKBIIXHQIERR-UHFFFAOYSA-N
- InChI
- InChI=1S/C15H11NO3/c17-14(18)9-16-12-7-3-1-5-10(12)15(19)11-6-2-4-8-13(11)16/h1-8H,9H2,(H,17,18)
- IUPAC Name
- 2-(9-oxo-9,10-dihydroacridin-10-yl)acetic acid
- SMILES
- OC(=O)CN1C2=CC=CC=C2C(=O)C2=CC=CC=C12
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0246234
- ChemSpider
- 34903
- BindingDB
- 50511089
- ChEBI
- 136036
- ChEMBL
- CHEMBL1569545
- ZINC
- ZINC000003878688
- PDBe Ligand
- 1K5
- PDB Entries
- 4jc5
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Terminated Treatment Endometrial Cancer 1 2 Unknown Status Treatment Recurrent or Persistent Endometrial Carcinoma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.197 mg/mL ALOGPS logP 2.55 ALOGPS logP 2.6 Chemaxon logS -3.1 ALOGPS pKa (Strongest Acidic) 3.68 Chemaxon pKa (Strongest Basic) -3.2 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 57.61 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 70.04 m3·mol-1 Chemaxon Polarizability 25.57 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 162.5425883 predictedDarkChem Lite v0.1.0 [M-H]- 162.2570883 predictedDarkChem Lite v0.1.0 [M-H]- 149.2741 predictedDeepCCS 1.0 (2019) [M+H]+ 162.7577883 predictedDarkChem Lite v0.1.0 [M+H]+ 162.9075883 predictedDarkChem Lite v0.1.0 [M+H]+ 151.66966 predictedDeepCCS 1.0 (2019) [M+Na]+ 162.7248883 predictedDarkChem Lite v0.1.0 [M+Na]+ 162.8011883 predictedDarkChem Lite v0.1.0 [M+Na]+ 157.58217 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:46 / Updated at September 28, 2023 05:48